One Biosciences Secures €15 Million Series A to Advance AI-Powered Single-Cell Cancer Diagnostics Platform
核心洞察
One Biosciences (搜索) raised €15 million in Series A financing led by Redmile Group (搜索) and Blast (搜索) to advance its OneMap (搜索) platform for single-cell cancer diagnostics.
The AI-powered platform generates detailed functional profiles of patient tumors to guide treatment decisions and improve patient selection for clinical trials.
Funding will accelerate clinical development of OneMap (搜索) and support strategic partnerships with pharmaceutical and biotech companies.
One Biosciences (搜索), a precision oncology biotech company, has secured €15 million in Series A financing to advance its AI-powered single-cell transcriptomic platform OneMap (搜索), designed to transform cancer diagnostics and treatment decision-making. The round was led by Redmile Group (搜索) and Blast (搜索), with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.
The funding brings One Biosciences (搜索)' total raised capital to over €20 million, including previous seed financing from Home Biosciences (搜索). The company specializes in clinical grade single-cell tumor transcriptomic profiling, a technology that creates detailed functional profiles of patient tumors to unlock insights for better clinical decision-making.
OneMap Platform Technology
OneMap (搜索) generates comprehensive functional profiles of patient tumors, providing real-time insights that could directly inform physician decision-making and improve patient care. The platform utilizes AI algorithms trained on proprietary single-cell patient datasets to predict responses to various classes of oncology therapeutics from clinical grade specimens.
Dr. Céline Vallot, co-founder of One Biosciences (搜索) and group leader at Curie Institute (搜索), emphasized the platform's predictive capabilities: "This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens."
Clinical Applications and Market Positioning
The technology aims to address limitations in current cancer care approaches. Dr. Mehdi Touat, Assistant Professor at Assistance Publique – Hôpitaux de Paris AP-HP and Paris Brain Institute, noted: "Widespread use of next generation sequencing profiling has led to substantial advances in cancer care but the clinical benefit remains limited to small patient subsets. We believe clinical grade single cell profiling has the potential to catalyse the next generation of diagnostic and therapeutic advances."
OneMap (搜索) is designed to support multiple aspects of cancer care, including treatment guidance, patient selection optimization, therapy development, and clinical trial enhancement. The platform's ability to provide detailed tumor profiling could help expand the patient populations that benefit from precision oncology approaches.
Strategic Development Plans
Proceeds from the Series A financing will accelerate the clinical development of the OneMap (搜索) platform and support the scaling of strategic partnerships with pharmaceutical and biotech companies. The company aims to position OneMap as a clinical tool to support precision oncology and drive innovation in cancer care.
Hedi Ben Brahim, CEO of One Biosciences (搜索), stated: "This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market."
The investment reflects growing interest in single-cell technologies for oncology applications, as the field moves toward more precise tumor characterization methods that could improve treatment outcomes across broader patient populations.